Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection

• Published in: Journal of viral hepatitis Vol. 11; no. 4; pp. 366 - 374
• Main Authors: Sypsa, V., Touloumi, G., Tassopoulos, N. C., Ketikoglou, I., Vafiadis, I., Hatzis, G., Tsantoulas, D., Akriviadis, E., Delladetsima, J., Demonakou, M., Hatzakis, A.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01.07.2004
• Subjects: Carcinoma, Hepatocellular - epidemiology; Carcinoma, Hepatocellular - virology; chronic hepatitis C; Disease Progression; fibrosis; Forecasting; Greece - epidemiology; Hepatitis C virus; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - epidemiology; Hepatitis C, Chronic - transmission; Humans; Incidence; Liver Cirrhosis - epidemiology; Liver Cirrhosis - virology; Liver Failure - epidemiology; Liver Failure - etiology; marker modelling; Models, Statistical; prediction; Prevalence; Probability; Greece
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/j.1365-2893.2004.00517.x

In this study, a comprehensive methodology for modelling the hepatitis C virus (HCV) epidemic is proposed to predict the future disease burden and assess whether the recent decline in the incidence of HCV may affect the future occurrence of cirrhosis and hepatocellular carcinoma (HCC) cases. Using the prevalence of HCV, the distribution of chronic hepatitis C (CHC) patients within the various transmission groups and their infection‐onset times, it was possible to reconstruct the incident infections per year in the past that progressed to CHC in Greece. The natural history of the disease was simulated in subcohorts of newly infected subjects using transition probabilities derived either empirically between fibrosis stages 0–4 or from literature review. Annual estimates of the incidence and prevalence of CHC by fibrosis stage, HCC and mortality in Greece were obtained up to 2030. HCV incidence peaked in the late 1980s at five new infections/10 000 person‐years. Under the assumption of 20–100% decline in HCV incidence after 1990, the cumulative number of incident cirrhosis and HCC cases from 2002–2030 was projected to be lower by 9.6–48.2% and 5.9–29.5%, respectively, than that estimated under the assumption of no decline. However, the prevalent cirrhotic/HCC cases and HCV‐related deaths are predicted to decline in the next 30 years only under the assumption of complete elimination of new HCV infections after 1990. Despite the progress in the reduction of HCV transmission, primary prevention does not seem adequate to reverse the rise in the incidence of cirrhosis and HCC.